Viewing Study NCT00337610



Ignite Creation Date: 2024-05-05 @ 4:53 PM
Last Modification Date: 2024-10-26 @ 9:25 AM
Study NCT ID: NCT00337610
Status: COMPLETED
Last Update Posted: 2016-05-12
First Post: 2006-06-14

Brief Title: Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus
Sponsor: Merck Sharp Dohme LLC
Organization: Merck Sharp Dohme LLC

Study Overview

Official Title: A Multicenter Double-Blind Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy
Status: COMPLETED
Status Verified Date: 2016-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic blood sugar control on metformin therapy
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
2006_017 None None None